April 16, 2018
The board of OvaScience Inc. on Friday escaped a derivative suit brought by shareholders who claim that misleading statements about an in vitro fertilization treatment caused a sharp stock drop, after a federal judge ruled the biotech company did not make any transactions requiring shareholder approval.